Atherothrombotic vascular disease, the cause of heart attacks, strokes, and sudden death, is the leading cause of death in the industrialized world. These acute vascular events are triggered by disruption of advanced atherosclerotic plaques that have large necrotic areas. Plaque necrosis is caused by macrophage (Mf) death, or """"""""apoptosis,"""""""" in advanced lesions. The PI's laboratory introduced the concept that endoplasmic reticulum (ER) stress in advanced lesional Mfs is an important mechanism of Mf death. ER stress induces a pro-apoptotic effector called CHOP, which conspires with other pro-apoptotic """"""""hits"""""""" to induce Mf death. The overall objective of this proposal is to expand these concepts in three critical areas: (a) discrimination of the roles of ER stress in advanced vs. early lesions and in Mfs vs. endothelial cells;(b) elucidation of the role of increased cytosolic Ca2+, a by-product of ER stress, in the multi-hit model of Mf apoptosis;and (c) assessment of whether decreased advanced lesional Mf apoptosis and plaque necrosis via genetic manipulation of the multi-hit/ER stress pathway has a beneficial effect in plaque disruption.
In Aim I, reciprocal bone marrow transplant (BMT) experiments using Chop-/- and Ldlr-/- mice will test the hypothesis that endothelial CHOP promotes early atherogenesis while Mf CHOP promotes advanced atherosclerosis.
Aim II will address the hypothesis that elevation of cytosolic calcium induced by ER stress amplifies two important pro-apoptotic pathways of the multi-hit model, one involving toll-like receptor 4 and c-Jun-NH(2)-terminal kinase, and the other involving Ca2+-calmodulin kinase II and serine-phosphorylated STAT1. BMT experiments in Aim III will test the hypothesis that Mf-STAT1 deficiency will decrease Mf death and plaque necrosis in advanced atherosclerotic lesions. The proposed link between plaque necrosis and plaque disruption will be addressed in Aim IV by determining whether plaque disruption in Apoe- /- mice with Mf-targeted expression of activated MMP9 is decreased in the setting of CHOP or combined CHOP/STAT1 deficiency. Through these studies, we hope to conceive novel therapeutic strategies to prevent advanced plaque progression and atherothrombotic vascular disease. Indeed, the Mf apoptosis pathway being studied here has been shown to be amplified in the setting of diabetes, which represents the major driving force predicted to increase atherothrombotic vascular disease in the immediate and longer term future.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL075662-09
Application #
8265930
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Kirby, Ruth
Project Start
2003-12-01
Project End
2013-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
9
Fiscal Year
2012
Total Cost
$398,475
Indirect Cost
$150,975
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Kamaly, Nazila; Fredman, Gabrielle; Fojas, Jhalique Jane R et al. (2016) Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis. ACS Nano 10:5280-92
Tabas, Ira (2016) Heart disease: Death-defying plaque cells. Nature 536:32-3
Subramanian, Manikandan; Proto, Jonathan D; Matsushima, Glenn K et al. (2016) Deficiency of AXL in Bone Marrow-Derived Cells Does Not Affect Advanced Atherosclerotic Lesion Progression. Sci Rep 6:39111
Ozcan, Lale; Ghorpade, Devram S; Zheng, Ze et al. (2016) Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance. Cell Rep 15:2214-25
Tabas, Ira (2016) 2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol :
Fredman, Gabrielle; Hellmann, Jason; Proto, Jonathan D et al. (2016) An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun 7:12859
Tabas, Ira; Bornfeldt, Karin E (2016) Macrophage Phenotype and Function in Different Stages of Atherosclerosis. Circ Res 118:653-67
Cai, Bishuang; Thorp, Edward B; Doran, Amanda C et al. (2016) MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc Natl Acad Sci U S A 113:6526-31
Fredman, Gabrielle; Kamaly, Nazila; Spolitu, Stefano et al. (2015) Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7:275ra20
Subramanian, Manikandan; Thorp, Edward; Tabas, Ira (2015) Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling. Circ Res 116:e13-24

Showing the most recent 10 out of 87 publications